

RECEIVED
CENTRAL FAX CENTER

AUG 23 2006

CLAIM AMENDMENTS

The following listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of Claims

1. (currently amended) A method for decreasing the appetite of an obese or overweight mammal comprising enterally administering to said mammal an amount of long-chain n-3 polyunsaturated fatty acid effective to decrease the appetite of said mammal, wherein the polyunsaturated fatty acid is administered in the form of a triacylglycerol to treat obesity or overweight in mammals that are obese or overweight.
2. (previously presented) The method according to claim 1 wherein said long-chain n-3 polyunsaturated fatty acid comprises docosahexaenoic acid.
3. (previously presented) The method of claim 2 wherein said long-chain n-3 polyunsaturated fatty acid is administered independent of arachidonic acid.
4. (currently amended) The method according to claim 1 wherein said long-chain n-3 polyunsaturated fatty acid is administered during a growth phase to an infant, child, or adolescent prior to or in conjunction with an appetite-impacting stimulus.
5. (previously presented) The method according to claim 1 wherein said long-chain n-3 polyunsaturated fatty acid is administered to an infant in a daily amount of 8 to 396 mg/kg body weight.
6. (previously presented) The method according to claim 1 wherein said long-chain n-3 polyunsaturated fatty acid is administered to a child or an adult in a daily amount of 84 to 15,832 mg.

7. (currently amended) A method for ~~modulating~~ decreasing the appetite of an overweight or obese mammal comprising enterally administering to said mammal an amount of long-chain n-3 polyunsaturated fatty acid and an amount of long-chain n-6 polyunsaturated fatty acid in relative amounts effective to ~~modulate~~ decrease the appetite of said mammal, wherein the polyunsaturated fatty acids are administered in the form of a triacylglycerol to treat obesity or overweight in mammals that are obese or overweight.

8. (previously presented) The method according to claim 7 wherein said long-chain n-3 polyunsaturated fatty acid comprises docosahexaenoic acid and said long-chain n-6 polyunsaturated fatty acid comprises arachidonic acid.

9. (currently amended) The method according to claim 7 wherein said long-chain n-3 polyunsaturated fatty acid is administered ~~during a growth phase~~ to an infant, child, or adolescent prior to or in conjunction with an appetite-impacting stimulus.

10. (previously presented) The method according to claim 7 wherein said long-chain n-3 polyunsaturated fatty acid is administered to an infant in a daily amount of 8 to 396 mg/kg body weight.

11. (previously presented) The method according to claim 7 wherein said long-chain n-3 polyunsaturated fatty acid is administered to a child or an adult in a daily amount of 84 to 15,832 mg.

12.-29 (canceled)